J. Wanders

23.5k total citations · 2 hit papers
132 papers, 19.6k citations indexed

About

J. Wanders is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, J. Wanders has authored 132 papers receiving a total of 19.6k indexed citations (citations by other indexed papers that have themselves been cited), including 101 papers in Oncology, 48 papers in Molecular Biology and 35 papers in Pulmonary and Respiratory Medicine. Recurrent topics in J. Wanders's work include Cancer Treatment and Pharmacology (68 papers), Cancer therapeutics and mechanisms (34 papers) and Colorectal Cancer Treatments and Studies (29 papers). J. Wanders is often cited by papers focused on Cancer Treatment and Pharmacology (68 papers), Cancer therapeutics and mechanisms (34 papers) and Colorectal Cancer Treatments and Studies (29 papers). J. Wanders collaborates with scholars based in Netherlands, United Kingdom and Belgium. J. Wanders's co-authors include Jaap Verweij, Elizabeth A. Eisenhauer, M. van Glabbeke, Richard Kaplan, Allan T. van Oosterom, Patrick Therasse, Michaele C. Christian, Susan G. Arbuck, Larry Rubinstein and Patrick Schöffski and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

J. Wanders

131 papers receiving 19.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

2000 13.6k citations Patrick Therasse, Susan G. Arbuck et al. profile →
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

2011 807 citations Javier Cortés, Joanne L. Blum et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Wanders Netherlands	38	11.1k	7.9k	4.2k	3.0k	2.8k	132	19.6k
Michaele C. Christian United States	28	9.4k 0.8×	6.9k 0.9×	3.6k 0.8×	2.9k 1.0×	2.7k 1.0×	48	18.5k
Patrick Therasse Belgium	23	10.9k 1.0×	8.6k 1.1×	3.6k 0.9×	3.2k 1.1×	3.8k 1.4×	36	20.5k
Allan T. van Oosterom Belgium	32	9.3k 0.8×	10.1k 1.3×	4.5k 1.1×	4.3k 1.4×	2.8k 1.0×	89	21.9k
E. Eisenhauer Canada	24	11.9k 1.1×	9.8k 1.2×	3.3k 0.8×	4.1k 1.4×	3.7k 1.3×	62	22.7k
Stephen J. Gwyther United Kingdom	18	12.4k 1.1×	10.3k 1.3×	3.2k 0.8×	4.3k 1.4×	3.8k 1.4×	30	23.4k
P. Therasse Belgium	27	12.4k 1.1×	10.5k 1.3×	3.2k 0.8×	4.2k 1.4×	4.2k 1.5×	57	24.1k
Margaret Mooney United States	22	12.1k 1.1×	9.8k 1.2×	3.2k 0.7×	4.1k 1.4×	3.9k 1.4×	70	23.0k
Jacek Jassem Poland	59	11.4k 1.0×	8.0k 1.0×	4.8k 1.1×	3.3k 1.1×	3.9k 1.4×	523	19.9k
Jean‐Yves Douillard France	55	11.2k 1.0×	10.0k 1.3×	3.7k 0.9×	2.1k 0.7×	2.4k 0.9×	266	17.0k
Volker Heinemann Germany	67	14.5k 1.3×	6.2k 0.8×	3.9k 0.9×	3.9k 1.3×	4.3k 1.6×	666	20.3k

Countries citing papers authored by J. Wanders

Since Specialization

Citations

This map shows the geographic impact of J. Wanders's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Wanders with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Wanders more than expected).

Fields of papers citing papers by J. Wanders

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Wanders. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Wanders. The network helps show where J. Wanders may publish in the future.

Co-authorship network of co-authors of J. Wanders

This figure shows the co-authorship network connecting the top 25 collaborators of J. Wanders. A scholar is included among the top collaborators of J. Wanders based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Wanders. J. Wanders is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Devriese, Lot A., Petronella O. Witteveen, Silvia Marchetti, et al.. (2012). Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment. Cancer Chemotherapy and Pharmacology. 70(6). 823–832. 37 indexed citations

Cardoso, Fátima, C.J. Twelves, Linda T. Vahdat, et al.. (2011). 5006 ORAL Eribulin Mesylate EMBRACE Study – Survival Analysis Excluding Patients Re-challenged With Therapies of the Same Class. European Journal of Cancer. 47. S331–S332. 2 indexed citations

Twelves, Chris, Danuta Z. Loesch, Joanne L. Blum, et al.. (2010). A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane.. Journal of Clinical Oncology. 28(18_suppl). CRA1004–CRA1004. 29 indexed citations

Twelves, Chris, et al.. (2010). Phase III Trials of Eribulin Mesylate (E7389) in Extensively Pretreated Patients With Locally Recurrent or Metastatic Breast Cancer. Clinical Breast Cancer. 10(2). 160–163. 83 indexed citations

Cortés, Javier, Linda T. Vahdat, Joanne L. Blum, et al.. (2010). Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine. Journal of Clinical Oncology. 28(25). 3922–3928. 164 indexed citations

Schöffski, Patrick, I. L. Ray-Coquard, Angela Cioffi, et al.. (2010). Activity of eribulin mesylate (E7389) in patients with soft tissue sarcoma (STS): Phase II studies of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC 62052).. Journal of Clinical Oncology. 28(15_suppl). 10031–10031. 13 indexed citations

Wanders, J., G. Edwards, Larisa Reyderman, et al.. (2010). 574 Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole (KET). European Journal of Cancer Supplements. 8(7). 181–181. 6 indexed citations

Therasse, Patrick, Susan G. Arbuck, Elizabeth A. Eisenhauer, et al.. (2005). New guidelines to evaluate the response to treatment in solid tumors. Breast Cancer. 12(S1). S16–S27. 476 indexed citations

Willemse, Pax H.B., Roberto Sorio, Anne Floquet, et al.. (2004). A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer. Investigational New Drugs. 23(1). 85–89. 10 indexed citations

10.

Awada, Ahmad, Ferry A.L.M. Eskens, Martine Piccart, et al.. (2002). Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours. European Journal of Cancer. 38(17). 2272–2278. 42 indexed citations

11.

Kaufmann, Andreas M., Peter L. Stern, Elaine M. Rankin, et al.. (2002). Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.. PubMed. 8(12). 3676–85. 170 indexed citations

12.

Smyth, John, Jan H.M. Schellens, Hilary Calvert, et al.. (2001). Activity of the dolastatin analogue, LU103793, in malignant melanoma. Annals of Oncology. 12(4). 509–511. 26 indexed citations

13.

Fumoleau, P., Hoffmann-La Roche, Christian Dittrich, et al.. (2000). Combined results of 4 phase I and pharmacokinetic (PK) studies of E7070, a novel chloroindolyl-sulphonamide inhibiting the activation of cdk2 and cyclin E. UCL Discovery (University College London). 7 indexed citations

14.

McLeod, HL, J. Wanders, A Setanoians, et al.. (1996). Multicentre phase II pharmacological evaluation of rhizoxin. British Journal of Cancer. 74(12). 1944–1948. 32 indexed citations

15.

Verweij, Jaap, J. Wanders, Thierry Gil, et al.. (1996). Phase II study of rhizoxin in squamous cell head and neck cancer. British Journal of Cancer. 73(3). 400–402. 13 indexed citations

16.

Huinink, W.W. ten Bokkel, A. Prové, Martine Piccart, et al.. (1994). A phase II trial with Docetaxel (Taxotere™) in second line treatment with chemotherapy for advanced breast cancer. Annals of Oncology. 5(6). 527–532. 117 indexed citations

17.

Catimel, G., Jan B. Vermorken, M. Clavel, et al.. (1994). A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. Annals of Oncology. 5(6). 543–547. 108 indexed citations

18.

Rodenhuis, Sjoerd, L.T. Vlasveld, R. Dubbelman, et al.. (1992). Feasibility study of high-dose carboplatin and etoposide in the salvage treatment of testicular cancer. Annals of Oncology. 3(6). 463–467. 10 indexed citations

19.

Beijnen, Jos H., et al.. (1992). Effect of Cisplatin-Containing Chemotherapy on Lithium Serum Concentrations. Annals of Pharmacotherapy. 26(4). 488–490. 5 indexed citations

20.

Oosterkamp, Hendrika M., J. Wanders, Jos H. Beijnen, et al.. (1991). Phase I study of vintriptol, a tryptophan ester of vinblastine. European Journal of Cancer and Clinical Oncology. 27(10). 1222–1226. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact